Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine.
Two clinical trials with Alice strain intranasal influenza vaccine were performed. In study no. 1 (utilizing random selection and double-blind control), 50 subjects received a bivalent inactivated influenza vaccine intramuscularly, 99 subjects received Alice strain vaccine intranasally, and 50 subjects received a placebo intranasally. No symptomatology could be attributed to the intranasal route of immunization. Convalescent-phase geometric mean titers of hemagglutination inhibition antibody were higher after intramuscular vaccination; seroconversion occurred in 16 or 17 recipients of the Alice strain, with initial titers of less than 1:8. Clinical and virologic surveillance for 20 weeks after vaccination revealed no influenza A illnesses in participants of the study. In study no. 2, 75% of the subjects with initial nasal antibody titers of less than 1:3 developed measurable nasal antibody after receiving Alice strain vaccine.